Project Grant R21DA064314
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the Regents of the University of Minnesota $139,998 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research elucidating the mechanisms and relevance of cocaine-induced plasticity of inhibitory G protein signaling in the prelimbic cortex. The project, which commenced on June 13, 2025, and concludes May 31, 2028, delivers basic neuroscience research investigating how repeated...
- Federal Grant Award Summary The University of Michigan received a $170,744 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded on June 17, 2025. The research project, titled "The Glucocorticoid Receptor as a Top-Down Neuromolecular Mechanism of Inhibitory Control," investigates the neural mechanisms underlying impulsivity and behavioral disinhibition in individuals with substance use disorder (SUD). The...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $600,580 to the Regents of the University of Minnesota (Office of Sponsored Projects Administration) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and deliver a three-week summer training workshop on reproducible research in brain imaging genetics. The award, effective August 1, 2025, through July 31, 2028, addresses a critical gap in workforce training by equipping graduate-level...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The University of Iowa a Project Grant totaling $466,500 under the Drug Use and Addiction Research Programs (CFDA 93.279) on August 15, 2025, for research activities extending through April 30, 2030. The award funds a research initiative titled "Molecular and Cellular Subtyping of Response to Drugs of Abuse in Co-Morbid Psychiatric Disorders." The research addresses a significant gap in addiction...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Miami's Office of Research Administration at the School of Medicine a $164,190 Project Grant on August 19, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The research project, titled "Dopamine Dysregulation and Oxidative Stress in HIV and Methamphetamine Induced Cognitive Impairment," addresses the overlapping public health epidemics of substance use disorder and...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded UC San Diego a $197,500 Project Grant effective September 1, 2025, through August 31, 2027, under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports the development and validation of an innovative in vivo Massively Parallel Reporter Assay (MPRA) platform designed to analyze the functional role of genetic variants and cis-regulatory elements implicated in substance use disorders (SUDs). The...
- Federal Grant Award Summary The University of Washington received a $139,812 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded on August 6, 2026, with a completion date of March 15, 2029. The research investigates serotonin and dopamine dynamics during kappa opioid receptor (KOR)-mediated aversion, addressing the mechanistic underpinnings of how stress increases vulnerability to drug reinforcement in...
- Federal Cooperative Agreement Award Summary The National Institute on Drug Abuse (NIDA) awarded $2,040,300 to the Regents of the University of Minnesota on September 1, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate a combined transcranial direct current stimulation (tDCS) and cognitive training intervention as an adjunctive treatment for opioid use disorder (OUD). The research addresses a critical clinical gap: despite widespread buprenorphine...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $613,786 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective September 1, 2025, through May 31, 2030. This award supports fundamental neuroscience research investigating dopamine D1 receptor (D1DR) signaling from subcellular compartments, specifically plasma membrane and Golgi signaling in medium spiny...
- Federal Project Grant Award Summary The University of Pennsylvania received a $247,702 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective July 31, 2025 through January 31, 2028. The grant funds basic neuroscience research investigating the role of mu-opioid receptors in the paraventricular nucleus of the thalamus (PVT) in stress-related behavioral phenotypes and opioid addiction vulnerability. The...
The University of Minnesota, through its Office of Sponsored Projects Administration, received a $423,500 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) on April 1, 2026, with a completion date of March 31, 2028. This research initiative will investigate the therapeutic potential of targeting muscarinic M5 receptors as a novel treatment approach for substance use disorders (SUDs). The project addresses a critical gap in addiction research by examining how stress-induced disruption of M5 receptor signaling in dopamine neurons increases vulnerability to drug reward and addiction. The research will employ advanced neuroscientific methodologies, including the cocaine conditioned place preference assay and selective genetic manipulation of dopamine neurons, to elucidate the molecular mechanisms underlying stress-potentiated drug reward. The project will generate novel preclinical research findings regarding M5 receptor regulation of dopamine transmission under stress conditions and will evaluate positive allosteric modulators as potential therapeutic interventions to mitigate stress-induced enhancement of drug reward sensitivity. By integrating stress factors into substance use disorder models and characterizing dopamine-specific M5 signaling, this research will provide critical foundational knowledge to support rational drug design and development of more effective addiction treatments. The deliverables will contribute to NIDA's mission to advance prevention, diagnosis, and treatment approaches for substance use and addiction through basic neuroscience research conducted at the University of Minnesota's Minneapolis campus.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $423.5k | 3/23/26 |